Company / EPS (Diluted)
AMICUS THERAPEUTICS, INC. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.51
FY2025
5-year range
-$1.48 / -$0.51
FY2021-FY2025
Trend
+37.8%
vs FY2024
Sector context
#73 of 204
Health Care
What the data says
At $-0.51, AMICUS THERAPEUTICS, INC.'s eps (diluted) ranks #73 of 204 in the Health Care sector. EPS (Diluted) has increased for 4 consecutive years, from $-1.48 in FY2021 to $-0.51 in FY2025.
Based on SEC 10-K filings.
-0.51 in FY2025.
Improved from $-0.92 to $-0.51 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#73 of 204 in Health CareTop 36% of 204This company -$0.51 Sector average -$0.89
▼
+42.5% above sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s eps (diluted) has grown for 4 consecutive years.
- In FY2025, eps (diluted) increased 37.8% year-over-year.
- Ranks #73 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.51 | +37.8% |
| FY2024 | -$0.82 | +10.9% |
| FY2023 | -$0.92 | +14.0% |
| FY2022 | -$1.07 | +27.7% |
| FY2021 | -$1.48 | -38.3% |
| FY2020 | -$1.07 | +27.7% |
| FY2019 | -$1.48 | - |
| FY2018 | - | - |
| FY2017 | -$1.20 | -29.0% |
| FY2016 | -$0.93 | +19.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026